A roundup of manufacturing news from Novartis, Eli Lilly and Company/EVA Pharma. Highlights below. 

* Novartis Begins Construction of Two New Radiopharma Facilities in the US 
* Lilly, Egypt’s EVA Pharma in Mfg Licensing Deal in Africa 

---

Novartis Begins Construction of Two New Radiopharma Facilities in the US 
Novartis has begun the construction of two new radioligand therapy (RLT) manufacturing facilities in the US. 

Novartis broke ground on a new facility at its site in Indianapolis, Indiana, which will produce radioisotopes for the manufacturing of RLTs. In Carlsbad, California, Novartis is establishing its third RLT manufacturing site in the US. Both facilities will be built with room for further expansion to enable the potential production of different isotopes, ligands, and RLTs.   

Source: Novartis 

---

Lilly, Egypt’s EVA Pharma in Mfg Licensing Deal in Africa 
Eli Lilly and Company and EVA Pharma, a Cairo, Egypt-based bio/pharmaceutical company, have entered into an agreement to expand access to Lilly’s baricitinib, a drug for treating rheumatoid arthritis, alopecia areata, atopic dermatitis, and COVID-19, to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. Baricitinib was discovered by Incyte, a Wilmington, Delaware-based bio/pharmaceutical company, and licensed to Lilly.  

EVA Pharma’s high-containment facility is set to begin sales of the locally manufactured baricitinib by 2026 to various African countries. This collaboration is part of the Lilly 30 x 30 initiative, which aims to improve access to healthcare for 30 million people living in resource-limited settings annually by 2030

Since 2021, EVA Pharma has been working with Lilly to ensure a sustainable supply of certain medicines across several African countries. Lilly and EVA Pharma are also collaborating to expand access to affordable insulin in 56 countries, most of which are low- to middle-income.

Source: Eli Lilly and Company